Investor

Novartis Bioventures

Last cheque observed Sep 2012. Silence since then is not evidence of inactivity: our sources miss unannounced rounds.

QuietGrowth equity

Series BSeries AGrowth

Cheques on record
0%of best year0cheques in 12 months, 10 on record
Since the last cheque5164days00hrs00min00sec
Median round$24MRounds led0 of 10Exits1 from the portfolioMostly inUnited States, 80%
Pitch Novartis Bioventures

Novartis Bioventures highlights

  1. 01

    10 rounds on record

  2. 02

    Mostly Series B and Series A: 60% of its rounds

  3. 03

    1 exits from the portfolio

What they do

Type
Growth equity (from a list, unverified)
Cheque size
Not stated
Cold pitches
Not stated

The record

Every round we can evidence, newest first10 appearances

  1. 2012

    3 rounds

  2. Sept
    F2GVenture · GB · fiercebiotech.com$30MWith 6 others
  3. Aug
    Aerpio TherapeuticsSeries A · US · finsmes.com$27MWith 6 others
  4. Jan
    Akebia TherapeuticsSeries B · US · finsmes.com$4.1MWith 7 others
  5. 2010

    1 round

  6. Sept
    Cylene PharmaceuticalsSeries D · US · socaltech.com$12MWith 6 others
  7. 2009

    1 round

  8. Nov
    PulmatrixSeries B · US · xconomy.com$30MWith 4 others
  9. 2008

    1 round

  10. Aug
    ESBATechSeries B · CH · fiercebiotech.com$22MWith 7 others
  11. 2007

    3 rounds

  12. Nov
    Ascent TherapeuticsSeries A · US · venturedeal.com$19MWith 3 others
  13. Mar
    PhenomixSeries C · US · phenomixcorp.com$55MWith 10 others
  14. Feb
    Trellis BioscienceSeries B · US · deals.venturebeat.com$10MWith 4 others
  15. 2005

    1 round

  16. Nov
    PTC TherapeuticsGrowth · US · ptct.client.shareholder.com$27MWith 10 others

An announcement gives the size of the round, not the size of this investor's cheque: the only rounds that imply a cheque are those where they were the sole named investor.

Exits from the portfolio

Companies it backed that were later bought or listed1 in all

PTC TherapeuticsListed$125MJun 2013

An exit counts when it came after the firm's first round in the company. From historical deal records.

Who they invest alongside

The investors most often in the same rounds as Novartis Bioventures. A count of rooms they were both in, not a relationship either has claimed.

Novartis Venture FundCorporate VC10rounds togetherHBM BioVenturesGrowth equity3rounds togetherAthenian Venture PartnersVC firm2rounds togetherBay City CapitalVC firm2rounds togetherDelphi VenturesVC firm2rounds togetherGeneChemGrowth equity2rounds togetherKearny Venture PartnersVC firm2rounds togetherTriathlon Medical Venture PartnersGrowth equity2rounds togetherVenture InvestorsVC firm2rounds together

Quick answers about Novartis Bioventures

What does Novartis Bioventures invest in?

Novartis Bioventures invests most often at Series B and Series A (60% of the rounds on record).

How active is Novartis Bioventures?

10 investments on record, 0 of them in the last 12 months. The most recent was in Sept 2012.

How big are Novartis Bioventures's cheques?

The median round it joins is $24M.

Does Novartis Bioventures lead rounds?

Rarely, if at all: none of its 10 investments on record names it as the lead.

Where does Novartis Bioventures invest?

Most of the companies it backs are in the United States (80%), the United Kingdom (10%) and Switzerland (10%).

Is Novartis Bioventures investing now?

No investments in the last 12 months; the latest was in Sept 2012.

Who does Novartis Bioventures invest alongside?

Most often Novartis Venture Fund (10 rounds together), HBM BioVentures (3 rounds together) and Athenian Venture Partners (2 rounds together).

What kind of investor is Novartis Bioventures?

Novartis Bioventures is a growth equity firm.

Raising now?

Find the investors who back rounds like yours, and keep every conversation on one fundraising board.

Find similar investorsOpen your CRM

Built from the rounds we watched, its filings and its own website, refreshed every night. How we count · Report a correction · Is this your firm? Claim it